Devonian Health Group, Inc. · TSXV:GSD
Devonian Health — Investor Presentation (July 2024)
33 slides from Devonian Health's investor presentation, July 2024
Slide 1: Corporate Presentation
DEVONIAN HEALTH GROUP TSXv – GSD l OTCQB – DVHGF Corporate Presentation
Slide 2: Cautionary Statements
Cautionary Statements This corporate presentation (“Presentation”) has been prepared by DEVONIAN HEALTH GROUP INC. (“DEVONIAN”) formulation of Thykamine in AD and its Phase 2 clinical trial of its twice-a-day formulation of Thykamine in RD and with market information provided by various third-party
Slide 3: Corporate Snapshot
Corporate Snapshot Clinical Stage Biopharmaceutical Company 1 5 Unique, Clinical multi-use Stage platform technology Biopharmaceutical with Company Multiple Clinical milestones expected in 2025-2026 multiple mechanisms of action: Pipeline within a product • Top-line results phase2/3 clinical trial i
Slide 4: Experienced Leadership
Experienced Leadership Clinical Stage Biopharmaceutical Company Luc Gregoire CPA, CA Colette Laurin CPA, CA Dr. André P. Boulet, PhD Pierre Montanaro Dr. Daniel Bouthillier, PhD President & CEO CFO Chief Scientific Officer President, Altius VP Research Healthcare Inc. Sipar, LP 4 TSXv – GSD l OTCQB
Slide 5: Board of Directors
Board of Directors Clinical Stage Biopharmaceutical Company Executives with extensive pharma and public company experience André Boulet Luc Grégoire CPA, CA David Baker Jean Forcione Ed Dahl Kathryn J. Gregory Louis Flamand PHD Founder & Chairman President & CEO Sipar, LP 5 TSXv – GSD l OTCQB – DVHG
Slide 6: Thykamine
Thykamine • Thylakoid-based active botanical ingredient (ABI) compound • First-In-Class ABI with Demonstrated Anti-Inflammatory, Anti-Oxidative and Immunomodulatory Properties • Multiple Indications---1st Target: Atopic Dermatitis (Eczema) Clinically Effective Convenient Dosing Safe, Well Tolerated
Slide 7: Thykamine Drug Development Pipeline
Thykamine Drug Development Pipeline Within A Product Key Focus on Dermatology Indication Preclinical Phase 1 Phase 2 Phase 3 Atopic Dermatitis (Adult – Topical) Atopic Dermatitis (Pediatric – Topical) Hand & Foot Syndrome associated to Chemotherapy Radiodermatitis associated to Radiotherapy Inflamma
Slide 8: Thykamine: Multifunctional Mode of Action
Thykamine : Multifunctional Mode of Action Platform Mechanisms of Action In-vitro and in Human studies have demonstrated: Complex isolated and optimized for clinical applications Anti-inflammatory effects Inhibition of pro-inflammatory cytokines Stimulates anti-inflammatory cytokines Synergistic eff
Slide 9: Thykamine Pipeline in a Product
Thykamine Pipeline in a Product Initial Focus on Dermatological Inflammatory Disorders Primary Secondary Atopic Dermatitis Demonstrated Proof-of- (ECZEMA) Concept in Mild-to-Moderate Ulcerative Colitis Hand & Foot Syndrome associated with Chemotherapy Radiodermatitis associated with Radiotherapy 9 T
Slide 10: Adult Atopic Dermatitis Phase 2 Trial
Adult Atopic Dermatitis (AD) Phase 2 Trial 1 Setting Stage for Phase 3 Trial PRIMARY ENDPOINT Proportion of patients with an IGA score of 0 (clear) or 1 (almost clear) and with at least a 2-grade improvement in IGA score from baseline. POPULATION *Adults with a diagnosis of AD for at least 6 months
Slide 11: Adult AD Phase 2 Trial: Primary Endpoint
Adult Atopic Dermatitis (AD) Phase 2 Trial 1 Setting Stage for Phase 3 Trial Proportion of patients achieving Primary Endpoint : IGA 0 or 1 and 2-point Reduction from Baseline 35.0 * 30.8 30.0 * 25.0 23.1 20.0 19.0 % 15.4 15.0 12.1 9.8 10.0 6.7 5.3 5.0 4.0 2.9 2.3 2.9 2.8 0.0 0.0 0.0 0.0 Day 7 Day 1
Slide 12: Adult AD Phase 2 Trial: Secondary Endpoint
Adult Atopic Dermatitis (AD) Phase 2 Trial 1 Setting Stage for Phase 3 Trial Proportion of patients achieving Secondary Endpoint : IGA 0 or 1 50.0 * 46.2 45.0 40.0 * * 35.9 35.0 33.3 33.3 30.0 26.8 Thykamine also met 25.0 24.2 other significant % Secondary Endpoints: 19.4 20.0 19.0 BSA 15.8 Prur
Slide 13: Significant Improvement in Key Secondary Endpoints Over Time
Significant Improvement in Key Secondary Endpoints by Treatment Group Over Time %BSA Pruritus a: p ≤ .05 vs baseline b: p ≤ .01 vs baseline c: p ≤ .001vs baseline d: p ≤ .05 vs vehicle e: p ≤.01 vs vehicle DLQI POEM f: p ≤.001 vs vehicle 13 TSXv – GSD l OTCQB – DVHGF 1 Lynde et al. J Drugs Dermatol.
Slide 14: Adult AD Phase 2 Trial: Safety and Tolerability
Adult Atopic Dermatitis (AD) Phase 2 Trial 1 Generally well-tolerated - Similar rate of adverse events reported for placebo and Thykamine Incidence of AEs, n (%) that were probably, possibly, or definitely related to study medication (safety population) Thykamine Thykamine Thykamine (PUR 0110) (PUR
Slide 15: Adult AD Phase 2 Trial: Competitive Landscape
Adult Atopic Dermatitis (AD) Phase 2 Trial 1 Competitive Landscape Competitive landscape vs new biotech products Efficacy rate similar to other new generation drugs % Patients reaching Mechanism of action Clinical development phase Patient population primary endpoint (p<0.05) Thykamine1 Immunomodula
Slide 16: Thykamine for Atopic Dermatitis: Leadership Position Opportunity
Thykamine for Atopic Dermatitis: Leadership Position Opportunity 101 million adults and 103 million children worldwide have AD. And approx. 70% of treated patients do not reach remission1 Unmet Medical Need Atopic Dermatitis Market 2021- • Better tolerability, safety & convenience 20272 • Safer main
Slide 17: Atopic Dermatitis: High Unmet Medical Need
Atopic Dermatitis: High Unmet Medical Need Burden and Unmet Need in Atopic Dermatitis Even with 90%-100% clearer Despite available therapies, goals are not achieved or sustained for skin, itch can still impact a many patients with AD1-5 patient’s life. Topical agents are widely Systemic therapies, t
Slide 18: Thykamine Milestones
Thykamine Milestones Key Targeted Milestones Within the Next 24 Months 1 Phase 2/3 Pediatric Atopic Dermatitis Top-line results 2 Phase 2 POC Hand & Foot Syndrome Top-line results 3 Radiodermatitis Pivotal study Top-line results 18 TSXv – GSD l OTCQB – DVHGF
Slide 19: Pediatric Development Program
Thykamine Pediatric Development Program
Slide 20: Global Atopic Dermatitis Market Summary
Global Atopic Dermatitis Market Summary 2028 Market value (US $B) Global AD Market $ 25.3B AD Drug Treatment Market $ 19.7B AD Topical Drug Market $ 13.3B AD Mild-to-Moderate Market (80.8% of Topical) $ 10.8B AD Pediatric Market (62,4%) $ 6.7B 20 Source : Global Atopic Dermatitis Treatment Market, -
Slide 21: Pediatric Mild-to-Moderate AD Treatment Landscape
Pediatric Mild-to-Moderate AD Treatment Landscape Patients with atopic dermatitis are at higher risk of multiple autoimmune diseases (1,2): • Alopecia areata, • Asthma • Celiac disease, Atopic eczema is more common in children, often • Crohn’s disease, developing before their first birthday. • Food
Slide 22: Focus on Pediatric Segment
Focus on Pediatric Segment 1 High value, less crowded market 2 Most treatments available can only be used on alternate basis 3 Younger patients (<12 years): underserved within this market 4 Leadership possibility as new therapeutic approach 22 TSXv – GSD l OTCQB – DVHGF
Slide 23: Pediatric AD Treatment Landscape
Pediatric AD Treatment Landscape Topical Corticosteroids Crisaborole topical Ruxolitinib topical Tacrolimus 0.03% Pimecrolimus 0.1% ointment 2% (Eucrisa) cream 1.5% (Elidel) (Opzelura) • Fear and anxiety PDE4 enzyme blocker First topical JAK inhibitor • Calcineurin inhibitor. • Calcineurin inhibitor
Slide 24: Focus on Pediatric Market Opportunity
Focus on Pediatric Market Opportunity Target approval in pediatric population with mild-to-moderate AD Phase 2/3 clinical study Randomized, double-blind, placebo Multiple drug concentration controlled, multisite clinical trial Targeting 300 patients Treatment duration 12 weeks 24 TSXv – GSD l OTCQB
Slide 25: Thykamine for Supportive Care
Thykamine for Supportive Care
Slide 26: Radiodermatitis Associated to Radiotherapy
Radiodermatitis Associated to Radiotherapy (1,2,3) Unmet Medical Need North America, Europe and Australia 50% 90% Large Patient Impact of patients diagnosed with of these patients will develop some • Pain/discomfort cancer will receive degree of radiodermatitis • Patient’s quality of life and well-b
Slide 27: Hand & Foot Syndrome Associated to Chemotherapy
Hand & Foot Syndrome Associated to Chemotherapy Unmet Medical Need Leadership Position Opportunity Large Patient Impact • Hand & Foot syndrome (HFS), is a well- • Pain/discomfort documented adverse effect of numerous • Patient’s quality of life and well-being • May cause diminution of chemotherapeut
Slide 28: IP and Corporate Summary
IP and Corporate Summary
Slide 29: Intellectual Property Portfolio
Intellectual Property Portfolio U.S. and international Indication Four (4) Trade marks patent estate covering • Extraction / Isolation / stabilization process • Inflammation • Devonian TM • Composition • Cardiovascular • Farm to Pharm TM • Route of Administration (oral; iv; ip; etc.) • Gastrointesti
Slide 30: State-of-the-Art Pharmaceutical Grade (cGMP) Facility
State-of-the-Art Pharmaceutical Grade (cGMP) EXTRACTION FACILITY • North American sourced raw material • 1,625 square meters • Water system upgradable to produce injectables / sterile eye solutions PHARMACEUTICAL GRADE • Facility with custom designed equipment At scale and further scalable • Full
Slide 31: Altius Health Care Inc.
ALTIUS HEALTH CARE INC. • Ultra-Generic Pharmaceutical Distribution Division • Focused on in-licensing original medicines for distribution in Canada • Off-patent products licensed directly from global pharmaceutical companies • Portfolio of 3 products • Simple merchandising business model with minim
Slide 32: Stock Information
1 Stock Information CAPITAL STRUCTURE Stock Exchanges TSXv: GSD OTCQB: DVHGF TOTAL OUTSTANDING SHARES 148,222,531 Warrants 11,722,317 Stock Options 16,087,721 FULLY DILUTED SHARE CAPITAL 176,032,569 1) As of May 8, 2024 32 TSXv – GSD l OTCQB – DVHGF
Slide 33: Thank You
Why Invest in Devonian? • Novel multi faceted prescription pharmaceutical • Addressing unmet needs in auto-immune inflammatory diseases • Body of pre-clinical and clinical works supports readiness for phase 3 • Leadership experienced in pharma scaling and capital markets • De-risked by contribution
Devonian Health Group — Investor Presentation (July 2024) on 6ix